No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY SCANDINAVIA&BALTICS

Finnish startup Solid IO raises funding to develop tumor-on-chip technology for precision oncology

Arctic Startupby Arctic Startup
February 25, 2025
Reading Time: 6 mins read
in SCANDINAVIA&BALTICS, VENTURE CAPITAL
Share on FacebookShare on Twitter
– Advertisement –

Helsinki-based medtech startup Solid IO has secured €800K in funding from Nordic Science Investments, BSV Ventures, Helsinki University Funds, and a private European investor. The company is developing patient-specific organ-on-chip technology to model tumor behavior and predict treatment responses in real time. The funding will support further development of the platform, aiming to improve treatment selection in immunotherapy and oncology drug development. Solid IO’s approach could help clinicians reduce trial-and-error in cancer treatment while providing pharmaceutical companies with more precise data for clinical trials.

Solid IO’s tumor-on-chip platform replicates the patient’s tumor microenvironment, generating high-accuracy, real-time data on how individual cancers respond to immunotherapies and combination treatments. By integrating bioengineering, organ-on-chip technology, the platform helps clinicians select the most effective therapy from day one, improving patient outcomes while reducing unnecessary side effects.

“Every cancer patient deserves a treatment plan based on their unique biology, adapting throughout the treatment journey,” said Noora Hujala, CEO and co-founder of Solid IO. “We are eliminating trial-and-error in cancer immunotherapy by bringing patient-specific tumor models into clinical use – this is the next evolution in precision oncology.”

Beyond improving personalized patient care, Solid IO’s platform is a game-changer for clinical trials and pharmaceutical R&D. The technology offers early patient stratification, biomarker validation, and treatment-response modeling, helping pharmaceutical companies reduce trial timelines, optimize patient selection, and accelerate the development of new immuno-oncology drugs.

“Organoids and organ-on-a-chip technology are transforming drug testing. Solid IO provides patient-specific insights in immuno-oncology, and we’re very proud to back this team, whose expertise is truly unique,” says Alexandra Gylfe, Partner at Nordic Science Investments.


Sandra Golbreich, Partner at BSV Ventures, added: “Despite all the advances in medicine, for too long we’ve relied on educated guesses in cancer treatment. It’s time to move on from uncertainty to real data, and from data to life-saving precision. Solid IO brings a new level of conscious, careful rigour to personalizing treatment for patients unlike any solution we’ve seen. This has a real world impact on people’s lives. We’re glad to partner with NSI on backing such a cutting-edge team.”

Solid IO was born out of a shared vision to transform cancer care through precision medicine. CSO, Dr. Haikala’s research together with Bassel Alsaed and a research team at the University of Helsinki focused on tumor-immune interactions, revealing the urgent need for patient-specific models that could guide real-world treatment decisions. CEO, Noora Hujala, with a background in commercial leadership roles in pharma and health care, got excited about the potential of turning this research into a clinically impactful solution. Together with the core team, they formed Solid IO, bringing together a multidisciplinary team of scientists, engineers, and biotech experts to push the boundaries of organ-on-chip technology.

“The possibility to predict individual patient responses to immunotherapies before treatment is a game-changer,” said Dr. Haikala. “By replicating how real tumors interact with the immune system, we are bridging the gap between research and clinical application – bringing us closer to truly personalized oncology.”


“What started as a research project has evolved into a company with the potential to impact millions of lives,” added Hujala. “We built Solid IO to bridge the gap between lab discoveries and clinical application – ensuring that every cancer treatment decision is based on real, patient specific data.”

A shared mission to end the guesswork in cancer care, the Solid IO team is engaging with leading research institutions and global pharma and biotech partners to accelerate the clinical adoption of tumor-on-chip technology, paving the way for a new era of precision oncology and immunotherapy.

Click to read more funding news.

– Advertisement –

Read the orginal article: https://arcticstartup.com/solid-io-raises-e800k/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

GREEN

Conapto and Vertical Data announce strategic partnership to drive scalable, sustainable and high-performance AI deployments

June 6, 2025
DACH

“We didn’t hear no bell” – German HealthTech startup doctorly kept from insolvency in full acquisition

June 5, 2025
FINTECH

Are Europe’s public markets a no-go for tech companies?

June 5, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

Where East meets West

Italy’s angels & incubators and venture capital weekly roundup. News from newcleo, Enec, Approxima, ENEA Tech, Biomedical, Panakès Partners , Club degli Investitori, NOB 4.0, CDP, and more

Italy’s angels & incubators and venture capital weekly roundup. News from newcleo, Enec, Approxima, ENEA Tech, Biomedical, Panakès Partners , Club degli Investitori, NOB 4.0, CDP, and more

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart